301201 诚达药业
已收盘 05-13 15:00:00
资讯
新帖
简况
诚达药业最新公告：前海晟泰拟减持不超4.89%股份
证券之星 · 05-11 19:09
诚达药业最新公告：前海晟泰拟减持不超4.89%股份
诚达药业：公司积极推广生物催化、连续流微反应等绿色前沿技术应用
证券之星 · 05-08
诚达药业：公司积极推广生物催化、连续流微反应等绿色前沿技术应用
每周股票复盘：诚达药业（301201）Q1净利增600.15%
证券之星 · 05-03
每周股票复盘：诚达药业（301201）Q1净利增600.15%
诚达药业（301201）2026年一季报简析：营收净利润同比双双增长
证券之星 · 04-29
诚达药业（301201）2026年一季报简析：营收净利润同比双双增长
诚达药业2025年营收4.06亿元增21.99%，CDMO成第一大收入来源，扣非净利仍亏2669.29万元
蓝鲸财经 · 04-27
诚达药业2025年营收4.06亿元增21.99%，CDMO成第一大收入来源，扣非净利仍亏2669.29万元
股市必读：诚达药业（301201）4月22日董秘有最新回复
证券之星 · 04-23
股市必读：诚达药业（301201）4月22日董秘有最新回复
4月10日诚达药业（301201）龙虎榜数据：机构净买入9365.15万元（3日）
证券之星 · 04-10
4月10日诚达药业（301201）龙虎榜数据：机构净买入9365.15万元（3日）
4月9日诚达药业（301201）龙虎榜数据：机构净买入5763.78万元
证券之星 · 04-09
4月9日诚达药业（301201）龙虎榜数据：机构净买入5763.78万元
诚达药业跌4.16% 2022年上市超募11亿光大证券保荐
中金财经 · 01-22
诚达药业跌4.16% 2022年上市超募11亿光大证券保荐
诚达药业：信达证券、国联民生等多家机构于1月14日调研我司
证券之星 · 01-14
诚达药业：信达证券、国联民生等多家机构于1月14日调研我司
股市必读：诚达药业（301201）1月13日收盘跌10.13%，主力净流入8420.93万元
证券之星 · 01-14
股市必读：诚达药业（301201）1月13日收盘跌10.13%，主力净流入8420.93万元
诚达药业（301201）披露使用部分超募资金永久补充流动资金议案获股东会通过，1月6日股价上涨1.64%
证券之星 · 01-06
诚达药业（301201）披露使用部分超募资金永久补充流动资金议案获股东会通过，1月6日股价上涨1.64%
每周股票复盘：诚达药业（301201）股东减持计划期满，持股降至5.36%
证券之星 · 01-03
每周股票复盘：诚达药业（301201）股东减持计划期满，持股降至5.36%
诚达药业（301201）发布2025年度持续督导现场检查报告，12月31日股价下跌3.85%
证券之星 · 2025-12-31
诚达药业（301201）发布2025年度持续督导现场检查报告，12月31日股价下跌3.85%
12月29日诚达药业发布公告，股东减持38.8万股
证券之星 · 2025-12-29
12月29日诚达药业发布公告，股东减持38.8万股
股市必读：诚达药业（301201）12月24日披露最新机构调研信息
证券之星 · 2025-12-25
股市必读：诚达药业（301201）12月24日披露最新机构调研信息
诚达药业：公司细胞治疗“心梗项目”“脑梗项目”已完成GMP厂房及设施设备的设计、安装、调试、确认
证券日报 · 2025-12-24
诚达药业：公司细胞治疗“心梗项目”“脑梗项目”已完成GMP厂房及设施设备的设计、安装、调试、确认
诚达药业：公司募投项目产能逐渐释放
证券日报 · 2025-12-24
诚达药业：公司募投项目产能逐渐释放
诚达药业：汇丰晋信、利幄基金等多家机构于12月24日调研我司
证券之星 · 2025-12-24
诚达药业：汇丰晋信、利幄基金等多家机构于12月24日调研我司
诚达药业（301201）披露拟使用部分超募资金永久补充流动资金，12月18日股价下跌0.49%
证券之星 · 2025-12-18
诚达药业（301201）披露拟使用部分超募资金永久补充流动资金，12月18日股价下跌0.49%
公司概况
公司名称：
诚达药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-20
主营业务：
诚达药业股份有限公司的主营业务是为跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务，左旋肉碱系列产品、原料药的研发、生产和销售以及干细胞药物的研发。公司的主要产品是定制类产品和服务、自主销售类产品、贸易类、其他业务。
发行价格：
72.69
{"stockData":{"symbol":"301201","market":"SZ","secType":"STK","nameCN":"诚达药业","latestPrice":41.17,"timestamp":1778655807000,"preClose":42.07,"halted":0,"volume":5536444,"delay":0,"changeRate":-0.0214,"floatShares":109000000,"shares":155000000,"eps":-0.0228,"marketStatus":"已收盘","change":-0.9,"latestTime":"05-13 15:00:00","open":42.06,"high":42.25,"low":41.02,"amount":229000000,"amplitude":0.0292,"askPrice":41.18,"askSize":71,"bidPrice":41.17,"bidSize":123,"shortable":0,"etf":0,"ttmEps":-0.0228,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778722200000},"marketStatusCode":5,"adr":0,"adjPreClose":42.07,"symbolType":"stock","openAndCloseTimeList":[[1778635800000,1778643000000],[1778648400000,1778655600000]],"highLimit":46.28,"lowLimit":37.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":154713824,"isCdr":false,"pbRate":3.1,"roa":"--","roe":"0.33%","epsLYR":-0.0787,"committee":0.575548,"marketValue":6370000000,"turnoverRate":0.051,"status":1,"floatMarketCap":4469000000},"requestUrl":"/m/hq/s/301201/wiki","defaultTab":"wiki","newsList":[{"id":"2634283455","title":"诚达药业最新公告：前海晟泰拟减持不超4.89%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2634283455","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634283455?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:09","pubTimestamp":1778497760,"startTime":"0","endTime":"0","summary":"诚达药业(301201.SZ)公告称，持股5.36%的股东深圳前海晟泰投资企业（有限合伙）（简称“前海晟泰”）计划以集中竞价或大宗交易方式减持公司股份不超过740万股(占公司剔除回购专户股份数后总股本比例4.89%)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100029533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101164","title":"诚达药业：公司积极推广生物催化、连续流微反应等绿色前沿技术应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633101164?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:48","pubTimestamp":1778201298,"startTime":"0","endTime":"0","summary":"证券之星消息，诚达药业05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：3.氮杂环丁烷小环结构是抗癌、神经、抗病毒创新药的核心骨架，请问贵公司在该类高难度小环中间体领域，是否有布局连续流加氢、电催化等绿色工艺？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800007656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632729156","title":"每周股票复盘：诚达药业（301201）Q1净利增600.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632729156","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632729156?lang=zh_cn&edition=full","pubTime":"2026-05-03 04:28","pubTimestamp":1777753690,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，诚达药业报收于41.24元，较上周的40.25元上涨2.46%。本周，诚达药业4月28日盘中最高价报42.95元。诚达药业当前最新总市值63.8亿元，在医疗服务板块市值排名30/51，在两市A股市值排名2894/5200。本周关注点业绩披露要点：诚达药业2026年一季报显示，归母净利润700.2万元，同比上升600.15%。股本股东变化股东户数变动截至2026年3月31日，诚达药业股东户数为1.43万户，较2025年12月31日增加1333.0户，增幅10.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557171","title":"诚达药业（301201）2026年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557171","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557171?lang=zh_cn&edition=full","pubTime":"2026-04-29 12:31","pubTimestamp":1777437116,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诚达药业发布2026年一季报。根据财报显示，诚达药业营收净利润同比双双增长。截至本报告期末，公司营业总收入1.28亿元，同比上升68.06%，归母净利润700.2万元，同比上升600.15%。本次财报公布的各项数据指标表现尚佳。持有诚达药业最多的基金为富国睿泽回报混合，目前规模为2.58亿元，最新净值2.0182，较上一交易日上涨0.42%，近一年上涨33.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900041059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630360531","title":"诚达药业2025年营收4.06亿元增21.99%，CDMO成第一大收入来源，扣非净利仍亏2669.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630360531","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630360531?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:11","pubTimestamp":1777284689,"startTime":"0","endTime":"0","summary":"数据显示，公司2025年实现营业收入4.06亿元，同比增长21.99%；归母净利润为-1192.58万元，同比增加57.56%；扣非净利润为-2669.29万元，同比增加53.72%。CDMO产品收入占比升至40.60%，首次成为第一大收入来源；左旋肉碱系列产品收入占比为58.73%，退居第二。2025年第四季度单季营业收入为1.21亿元；归母净利润为-2869.91万元；扣非净利润为-3059.55万元，当季扣非净利润亏损额高于全年累计值，表明全年经营性减亏成果未能延续至年末，Q4盈利压力明显加大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1777283201647343535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["301201","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629648024","title":"股市必读：诚达药业（301201）4月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2629648024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629648024?lang=zh_cn&edition=full","pubTime":"2026-04-23 02:34","pubTimestamp":1776882850,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，诚达药业报收于40.6元，下跌1.22%，换手率4.48%，成交量4.87万手，成交额1.97亿元。董秘最新回复投资者： 目前行业内在仲丁基锂连续流规模化生产上已出现明显技术领先企业，该技术直接决定高难度创新药分子的可开发性与商业化效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300004536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626195842","title":"4月10日诚达药业（301201）龙虎榜数据：机构净买入9365.15万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2626195842","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626195842?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:15","pubTimestamp":1775812519,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月10日公布的交易公开信息显示，诚达药业因连续三个交易日内，跌幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月10日收盘，诚达药业报收于46.31元，下跌12.62%，换手率22.2%，成交量24.1万手，成交额11.92亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入9365.15万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000029270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626900281","title":"4月9日诚达药业（301201）龙虎榜数据：机构净买入5763.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626900281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626900281?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:13","pubTimestamp":1775726026,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月9日公布的交易公开信息显示，诚达药业因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月9日收盘，诚达药业报收于53.0元，下跌15.54%，换手率24.99%，成交量27.12万手，成交额15.55亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入5763.78万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900027238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605461424","title":"诚达药业跌4.16% 2022年上市超募11亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2605461424","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605461424?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:21","pubTimestamp":1769073672,"startTime":"0","endTime":"0","summary":"中国经济网北京1月22日讯 诚达药业 今日收报39.67元，跌幅4.16%。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构为光大证券，保荐代表人为杨科、范国祖。上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。 诚达药业首次公开发行股票的发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 2023年7月3日，诚达药业发布2022年度权益分派实施公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260122/31964189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1564","BK0188","BK0276","601788","BK0028","06178","301201","BK0239","BK1147","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603690466","title":"诚达药业：信达证券、国联民生等多家机构于1月14日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2603690466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603690466?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:31","pubTimestamp":1768390264,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月14日诚达药业发布公告称信达证券贺鑫、国联民生杨涛、鑫元基金白伊贝、中银资管李明蔚、国泰基金张小皮、康泰资产马步云于2026年1月14日调研我司。诚达药业主营业务：跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务,以及左旋肉碱系列产品、原料药的研发、生产和销售。该股最近90天内共有1家机构给出评级，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400035957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1147","601456","01456","BK0276","601059","301201","BK1564","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603631668","title":"股市必读：诚达药业（301201）1月13日收盘跌10.13%，主力净流入8420.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603631668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603631668?lang=zh_cn&edition=full","pubTime":"2026-01-14 01:29","pubTimestamp":1768325348,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，诚达药业报收于45.88元，下跌10.13%，换手率15.09%，成交量16.38万手，成交额8.11亿元。当日关注点来自交易信息汇总：诚达药业股价1月13日收跌10.13%，报45.88元，当日成交1638.2万元，已连续2日下跌。前10个交易日主力资金累计净流入2.34亿元，股价累计上涨8.99%；融资余额累计增加1.97亿元，融券余量累计增加0股。资金流向1月13日主力资金净流出4368.13万元，游资资金净流入4740.7万元，散户资金净流出372.57万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400000822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601694813","title":"诚达药业（301201）披露使用部分超募资金永久补充流动资金议案获股东会通过，1月6日股价上涨1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601694813","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601694813?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:16","pubTimestamp":1767708979,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，诚达药业报收于45.12元，较前一交易日上涨1.64%，最新总市值为69.81亿元。公司近日发布公告称，诚达药业于2026年1月6日召开2026年第一次临时股东会，会议审议通过《关于使用部分超募资金永久补充流动资金的议案》。出席会议的股东共82人，代表股份67,810,080股，占公司有表决权股份总数的44.7683%。该项议案获得出席会议有效表决权股份总数的99.9484%同意，反对占比0.0509%，弃权占比0.0006%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600609889","title":"每周股票复盘：诚达药业（301201）股东减持计划期满，持股降至5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600609889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600609889?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:16","pubTimestamp":1767384970,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，诚达药业报收于40.7元，较上周的41.95元下跌2.98%。本周，诚达药业12月30日盘中最高价报43.27元。公司公告汇总关于持股5%以上股东减持计划时间届满的公告诚达药业股份有限公司于2025年12月29日发布公告，持股5%以上股东深圳前海晟泰投资企业减持计划时间届满。减持后，前海晟泰持有公司股份8,116,797股，占剔除回购专户股份数后总股本的5.36%。本次减持未超出此前披露的减持计划，不影响公司控制权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595781477","title":"诚达药业（301201）发布2025年度持续督导现场检查报告，12月31日股价下跌3.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595781477","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595781477?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:08","pubTimestamp":1767175696,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，诚达药业报收于40.7元，较前一交易日下跌3.85%，最新总市值为62.97亿元。该股当日开盘42.11元，最高42.41元，最低40.25元，成交额达2.45亿元，换手率为5.51%。近日，光大证券股份有限公司发布了《关于诚达药业股份有限公司2025年度持续督导现场检查报告》。公告显示，光大证券于2025年12月16日对诚达药业开展2025年度持续督导现场检查，检查内容包括公司治理、内部控制、信息披露、募集资金使用、业绩情况等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595780741","title":"12月29日诚达药业发布公告，股东减持38.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780741","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595780741?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:01","pubTimestamp":1767013302,"startTime":"0","endTime":"0","summary":"证券之星消息，12月29日诚达药业发布公告《诚达药业:关于持股5%以上股东减持计划时间届满的公告》，其股东深圳前海晟泰投资企业(有限合伙)于2025年10月23日合计减持38.8万股，占公司目前总股本的0.2508%，变动期间该股股价下跌3.77%，截止10月23日收盘报32.7元。股东增减持详情见下表：根据诚达药业2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900034961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594409753","title":"股市必读：诚达药业（301201）12月24日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2594409753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594409753?lang=zh_cn&edition=full","pubTime":"2025-12-25 02:58","pubTimestamp":1766602690,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，诚达药业报收于41.34元，下跌0.86%，换手率3.37%，成交量3.66万手，成交额1.51亿元。当日关注点来自交易信息汇总：12月24日主力资金净流出527.14万元，游资资金净流入432.67万元。来自机构调研要点：诚达药业已交付部分小核酸订单，募投项目产能逐步释放，可满足多阶段订单需求。机构调研要点公司目前小核酸业务主要为亚磷酰胺单体和GalNac递送系统，不同单体和递送系统的单价各异，其中递送系统价格高于单体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500001404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593701964","title":"诚达药业：公司细胞治疗“心梗项目”“脑梗项目”已完成GMP厂房及设施设备的设计、安装、调试、确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2593701964","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593701964?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:09","pubTimestamp":1766585340,"startTime":"0","endTime":"0","summary":"证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司细胞治疗“心梗项目”“脑梗项目”已完成GMP厂房及设施设备的设计、安装、调试、确认；完成脐带间充质干细胞的原代分离、培养及冻存的技术转移，建立了种子库、主细胞库及工作细胞库；完成分析方法的开发和验证；启动工艺验证，为IND申报做准备。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxizf4303173.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxizf4303173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593640858","title":"诚达药业：公司募投项目产能逐渐释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2593640858","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593640858?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:09","pubTimestamp":1766585340,"startTime":"0","endTime":"0","summary":"证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司募投项目产能逐渐释放，能满足客户不同产品、不同阶段、不同规模订单的需求。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxizc4140876.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxizc4140876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593947911","title":"诚达药业：汇丰晋信、利幄基金等多家机构于12月24日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593947911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593947911?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:01","pubTimestamp":1766574094,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月24日诚达药业发布公告称汇丰晋信晏建树 陈平 王佳怡、利幄基金向遥于2025年12月24日调研我司。诚达药业主营业务：跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务,以及左旋肉碱系列产品、原料药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592901012","title":"诚达药业（301201）披露拟使用部分超募资金永久补充流动资金，12月18日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592901012","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592901012?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:05","pubTimestamp":1766066736,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，诚达药业报收于40.93元，较前一交易日下跌0.49%，最新总市值为63.32亿元。该股当日开盘40.72元，最高42.11元，最低40.14元，成交额达1.41亿元，换手率为3.13%。股权登记日为2025年12月26日。本次股东会将审议《关于使用部分超募资金永久补充流动资金的议案》，该议案为普通决议议案，需经出席股东会的股东所持表决权过半数通过。中小投资者投票结果将单独统计披露。会议采取现场表决与网络投票相结合方式，登记时间截至2025年12月29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800037928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778670552724,"stockEarnings":[{"period":"1week","weight":0.0201},{"period":"1month","weight":-0.0916},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.0261},{"period":"1year","weight":0.9856},{"period":"ytd","weight":0.0337}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0573},{"period":"3month","weight":0.02},{"period":"6month","weight":0.0459},{"period":"1year","weight":0.2509},{"period":"ytd","weight":0.0619}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诚达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14295人(较上一季度增加10.28%)","perCapita":"7593股","listingDate":"2022-01-20","address":"浙江省嘉兴市嘉善县惠民街道黄河路36号","registeredCapital":"15471万元","survey":" 诚达药业股份有限公司的主营业务是为跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务，左旋肉碱系列产品、原料药的研发、生产和销售以及干细胞药物的研发。公司的主要产品是定制类产品和服务、自主销售类产品、贸易类、其他业务。","listedPrice":72.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诚达药业,301201,诚达药业股票,诚达药业股票老虎,诚达药业股票老虎国际,诚达药业行情,诚达药业股票行情,诚达药业股价,诚达药业股市,诚达药业股票价格,诚达药业股票交易,诚达药业股票购买,诚达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}